Commenting on the quarter, Michael S. Weiss, Keryx's Chairman and Chief
Executive Officer, said, "The first quarter of 2008 has been the most
challenging one for the Company since I joined back in 2002. However, with
the restructuring now substantially complete, I believe that Keryx is now
well-positioned to move Zerenex and Perifosine forward through advanced
clinical development." Weiss continued, "On the financial side, with
respect to our strategic licensing arrangement for Zerenex in Japan, the
Company has received an additional $8 million milestone payment from
JT/Torii and, coupled with our existing cash resources and reduced overhead
structure, we believe that we are well-positioned to focus our resources on
creating value in our drug candidates."
On Monday, May 12, 2008, at 8:30am EDT, the Company will host an
investor conference call to provide a brief financial overview of the
Company's first quarter financial results.
Executive Officer, said, "The first quarter of 2008 has been the most
challenging one for the Company since I joined back in 2002. However, with
the restructuring now substantially complete, I believe that Keryx is now
well-positioned to move Zerenex and Perifosine forward through advanced
clinical development." Weiss continued, "On the financial side, with
respect to our strategic licensing arrangement for Zerenex in Japan, the
Company has received an additional $8 million milestone payment from
JT/Torii and, coupled with our existing cash resources and reduced overhead
structure, we believe that we are well-positioned to focus our resources on
creating value in our drug candidates."
On Monday, May 12, 2008, at 8:30am EDT, the Company will host an
investor conference call to provide a brief financial overview of the
Company's first quarter financial results.
